Daylight Biotherapeutics

Xilio Therapeutics

This biotechnology company develops tumour-activated immuno-oncology therapies designed to treat patients with solid cancers while reducing systemic side effects.

A2 Biotherapeutics

This company develops logic-gated T-cell therapies to treat patients with solid tumours by selectively targeting cancer cells while sparing healthy tissue.

T-Therapeutics

The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.

Cytospire Therapeutics

This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.

Bicara Therapeutics

This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.

Waypoint Bio

This company develops cell therapies for solid tumours using a spatial biology and machine learning platform to assist patients with difficult-to-treat cancers.

3T Biosciences

The company develops T-cell receptor therapeutics and target identification technologies for oncology patients to treat solid tumours.

Modulari-T Biosciences

This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.